Background {#Sec1}
==========

Multiple Sclerosis (MS) is a chronic autoimmune disease of the brain and spinal cord of the central nervous system (CNS) that is characterized by demyelination, inflammation and axonal degeneration, resulting in serious disability in young adults \[[@CR1], [@CR2]\]. It is estimated that above 2.5 million people in the world suffer from MS \[[@CR3]\]. Although the main etiology of the disease remains obscure, it is thought that both genetic and environmental factors and their interactions are critical in disease development \[[@CR4]--[@CR6]\]. Especially, the role of genetic factors in the pathogenesis of MS has been established by family and twin studies. Accordingly, the heritability of MS is estimated to be about 25--80% \[[@CR7]--[@CR9]\]. As noted in recent studies, several genes, including interleukin (IL) 6, IL-12, vitamin D receptor (VDR), Signal transducer and activator of transcription (STAT) 4, Protein tyrosine phosphatase, non-receptor type 22 (PTPN22), CD40, programmed cell death (PD1/PD-L1), and Matrix metalloproteinases (MMPs) have been correlated with MS and attracted much attention to investigating more genetic factors contributing to MS risk \[[@CR10]--[@CR17]\].

MMPs are zinc-dependent endopeptidases enzymes that play an important role in many physiological and pathological processes including inflammation, invasiveness of tumor, metastasis, and angiogenesis by the degradation of the extracellular matrix and basement membrane (BM) \[[@CR18], [@CR19]\]. On the basis of structure and in terms of substrate specificity, MMPs are divided into six groups: collagenases (MMP-1, − 8, − 13, − 18), gelatinases (MMP-2, − 9), stromelysins (MMP-3, − 10, − 11), matrilysins (MMP-7, − 26), membrane-type MMPs (MMP-14, − 15, − 16, − 17,-24, − 25) and other non-classified MMPs (MMP-12, − 19, − 20, − 21, − 22, − 23, − 27, − 28) that is encoded by a separate gene and has a different tissue distribution and bioactive function \[[@CR20]--[@CR22]\]. MMPs have a critical role in the pathogenesis of MS by inducing migration of immune cells through the blood-brain barrier (BBB) into the CNS, which seems essential during the formation of inflammatory lesions \[[@CR23]\].

The regulation of MMP family genes expression has not been understood, but it has been demonstrated that genomic sequence of MMP family genes is polymorphic; it is of added attention to ascertain which polymorphisms in MMP family genes have functional potentials to influence the final bioavailability of family member(s) and therefore the progression of MS \[[@CR14], [@CR24]--[@CR26]\]. Several studies have evaluated the association between MMP family gene polymorphisms and MS risk; but the results are often inconsistent \[[@CR27]--[@CR29]\]. Therefore, we performed a meta-analysis to attain a consistent conclusion of the association between the MMP-91562 C/T (rs3918242), MMP-3 (− 1612 5A/6A), and MMP-2 (− 1306 C/T) gene polymorphisms and susceptibility to MS.

Methods {#Sec2}
=======

This meta-analysis was performed by sticking to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR30]\]. The current meta-analysis does not contain any studies with human participants or animals performed by any of the authors.

Search strategy {#Sec3}
---------------

The initial comprehensive and systematic search was conducted in Medline, Scopus, and PubMed databases. To be assured of our search, combination of following key words and Medical Subject Headings (Mesh) terms were used: ("matrix metalloproteinase" \[Mesh\] OR "MMP" OR "gelatinase") AND ("multiple sclerosis" OR "MS") AND ("single nucleotide polymorphism" OR "SNP" OR "polymorphisms" OR "mutation" OR "variation"). We retrieved all studies published prior to January 2020. The references of reviews and eligible studies were cross-checked to prevent missing of any eligible study which was not identified by primary search.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies considered eligible if met the following criteria: 1) Publications evaluating the association between MMP family gene polymorphism and susceptibility to MS as main outcome; 2) Publications with case and control groups (Case-control design and cohort design); 3) Publications which report odds ratio (OR) and 95% confidence interval (CI) or crud data to calculate these items; 4) Publications with sufficient data such as genotype distribution and allele frequency. Publications like reviews, meta-analysis, case reports, book chapters, letter to editors, conference abstracts, as well as duplicates were all excluded.

Data extraction and quality assessment {#Sec5}
--------------------------------------

We identified eligible studies by sticking to the inclusion and exclusion criteria, and to perform meta-analysis following data were extracted: the first author's name, journal and year of publication, country of origin, ethnicity, number of subjects in the case and the control groups for each gender, mean or range of age, genotyping method, genotype counts in the case and control groups. It is noteworthy that all procedure of data extraction was performed by two authors independently and possible discrepancy was solved by consensus. Furthermore, the quality of each study was assessed using the Newcastle-Ottawa Scale (NOS) criteria \[[@CR31]\]. Studies with scores 0--3, 4--6 or 7--9 were of low, moderate, or high-quality, respectively.

Statistical analysis {#Sec6}
--------------------

We used Pearson's chi-square test in control groups to estimate Hardy--Weinberg equilibrium(HWE) for each study. In this study OR with 95% CI was used to assess the strength of the association between MMP family gene polymorphism and MS risk. The genotype model which defined for MMP-2, MMP-3, and MMP-9 were as follow: **MMP-2** (Dominant model \[TT + CT vs. CC\], Recessive model \[TT vs. CT + CC\], Allelic model \[T vs. C\], Homozygote contrast \[TT vs. CC\], and Heterozygote contrast \[CT vs. CC\]); **MMP-3** (Dominant model \[6A6A + 5A6A vs. 5A5A\], Recessive model \[6A6A vs. 5A6A + 5A5A\], Allelic model \[6A vs. 5A\], Homozygote contrast \[6A6A vs. 5A5A\], and Heterozygote contrast \[5A6A vs. 5A5A\]); **MMP-9** (Dominant model \[TT + CT vs. CC\], Recessive model \[TT vs. CT + CC\], Allelic model \[T vs. C\], Homozygote contrast \[TT vs. CC\], and Heterozygote contrast \[CT vs. CC\]). Possible heterogeneity in this study was estimated by Q-test and *I*^*2*^ test \[[@CR32], [@CR33]\]. Accordingly, a *P* value\< 0.10 of *Q*-test and *I*^*2*^ \< 50% demonstrate no evidence of heterogeneity and fixed effect model (FEM) was used \[[@CR34]\]. But, if *P* value\> 0.10 for *Q*-test and *I*^*2*^ \> 50%, then the study was considered heterogeneous and random effect model (REM) was applied \[[@CR35]\]. Furthermore, publication bias was measured by Egger's regression test, Begg's adjusted rank correlation test, and visual examination of the funnel plot (*P* value\< 0.05 was considered statistically significant) \[[@CR36]\]. Finally, we performed sensitivity analysis to observe the impact of any individual study on the pooled OR. Statistically analyses were carried out using STATA (version 14.0; Stata Corporation, College Station, TX) and SPSS (version 23.0; SPSS, Inc. Chicago, IL).

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

Based on aforementioned key words, primary search generated 401 studies that 24 studies were duplicates. The other 377 studies were screened according to the inclusion and exclusion criteria. Taken to gather, 331 studies were excluded by title and abstract screening and 31 studies were excluded after full text examination. Ultimately, 15 studies matched with the inclusion criteria and selected for quantitative analysis. Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} summarize the characteristics and genotype frequency of the included studies. The mean age of case and control groups were between 30 and 40. All studies had good methodological score ranging from 5 to 8 and were published between 2000 to 2019. Among included studies, the Restriction fragment length polymorphism (RFLP)-PCR was used as a common genotyping model. The screening workflow and study selection process are shown in Fig. [1](#Fig1){ref-type="fig"}. Table 1Characteristics of studies included in meta-analysisStudy authorYearCountryEthnicityTotal cases/controlsSex cases/controlsGenotyping methodMean age\
Cases/ControlsQuality score**MMP9** Nelissen et al.2000SwedenEuropean199/146M = NRF=NRPCR-RFLPNR/NR6 Zivkovic et al.2007SerbiaEuropean187/282M = 67/140F = 120/142Touch Down PCR35.5 ± 10.1/40.8 ± 14.87 Benesova et al.2008Czech RepublicEuropean244/132M = 63/45F = 181/87PCR-SSP38.4 ± 10.2/35.6 ± 11.77 Mirowska-Guzel et al.2009PolandEuropean234/190M = 66/76F = 168/114PCR-RFLP40.09 ± 10.19/40.09 ± 10.197 Fernandes et al.2009BrazilSouth-American158/191M = 41/54F = 117/137PCR-RFLP38.7 ± 13/35.6 ± 9.56 La Russa et al.2010ItalyEuropean243/173M = 96/107F = 147/66PCR-RFLP41.1 ± 12.2/28.5 ± 9.47 Valado et al.2017PortugalEuropean169/183M = 48/63F = 121/120PCR-RFLP41.44 ± 0.84/39.09 ± 0.966 Ibrahim et al.2019EgyptAfrican50/100M = 18/NRF = 32/NRPCR-RFLP32.9 ± 8.1/NR5 Sabbagh et al.2019IranAsian100/105M = 37/41F = 63/64PCR-ARMS42.89 ± 10.48/46.52 ± 8.905 Sadr et al.2019IranAsian170/200M = 121/142F = 49/58PCR-RFLP33.34 ± 7.91/31.88 ± 9.797**MMP3** Djuric et al.2008SerbiaEuropean184/236M = NRF=NRTouch Down PCRNR/NR7 Rahimi et al.2016IranAsian121/106M = 24/17F = 97/89PCR-RFLP35.3 ± 9.1/34.5 ± 11.46**MMP2** Benesova et al.2008Czech RepublicEuropean240/132M = 60/45F = 180/87PCR-SSP38.4 ± 10.2/35.6 ± 11.77 Aksoy et al.2016TurkeyEuropean102/102M = 76/75F = 26/27Taq man36.69 ± 8.33/35.93 ± 8.206 Liutkeviciene et al.2018LithuaniaEuropean26/26M = NRF=NRTaq man36/345Table 2Distribution of genotype and allele frequencies among MS patients and controlsStudy authorMS casesHealthy controlP-HWEMAFCCCTTTCTCCCTTTCT**MMP9** Nelissen et al.14351533761102404244480/9730/164 Zivkovic et al.14641033341200748474900/7160/16 Benesova et al.1915034325687423216480/4240/182 Mirowska-Guzel et al.1281033359109136504322580/8110/153 Fernandes et al.11735626947156323344380/3690/099 La Russa et al.16473640185147251319270/9540/078 Valado et al.13035429543145344324420/2470/115 Ibrahim et al.28211772378211177230/7510/115 Sabbagh et al.11355457143424221126840/0870/4 Sadr et al.96601425288163334359410/1440/103**MMP2** Benesova et al.1438413370110754017190740.0040.28 Aksoy et al.405661366877250179250.150.123 Liutkeviciene et al.1970457190108204881480.380.233**Study authorMS casesHealthy controlP-HWEMAF5A/5A5A/6A6A/6A5A6A5A/5A5A/6A6A/6A5A6AMMP3** Djuric et al.241025815021837130692042680.060.568 Rahimi et al.366527217016738691430.0060.675P-HWE, *p*-value for Hardy--Weinberg equilibrium; *MAF* Minor allele frequency of control groupFig. 1Flow diagram of study selection process

*Meta-analysis of MMP-9 (*− 1562 C/T*) and risk of MS* {#Sec9}
------------------------------------------------------

A total of 10 eligible studies with 1754 cases and 1702 controls were included in quantitative analysis. Of them, six studies were conducted in European countries \[[@CR27], [@CR29], [@CR37]--[@CR40]\], two studies in Asian countries \[[@CR41], [@CR42]\], one study was in Egypt \[[@CR43]\] and one in Brazil \[[@CR44]\]. The pooled OR divulged a strong positive association between *MMP-9* gene rs34016235 polymorphism and risk of MS and announced this SNP as a risk factor for MS (Fig. [2](#Fig2){ref-type="fig"}). In details, dominant model (OR = 1.62, 95% CI = 1.03--2.53, *P* = 0.03), recessive model (OR = 2.69, 95% CI = 1.68--4.29, *P* \< 0.001), allelic model (OR = 1.51, 95% CI = 1--2.28, *P* = 0.04), TT vs. CC model (OR = 3.20, 95% CI = 1.87--5.46, *P* \< 0.001), and CT vs. CC model (OR = 1.53, 95% CI = 1.02--2.28, *P* = 0.04). FEM was used for recessive and homozygote compressions and REM was applied for dominant, heterozygote, and allelic models. The results of pooled ORs, heterogeneity tests and publication bias tests in different analysis models are shown in Table [3](#Tab3){ref-type="table"}. Fig. 2Forest plot of the association between *MMP-9* gene polymorphism and MS risk: A; dominant model, B; recessive modelTable 3Main results of pooled ORs in meta-analysis of *MMP* family gene polymorphismSubgroupSample sizeTest of associationTest of heterogeneityTest of publication bias (Begg's test)Test of publication bias (Egger's test)Genetic modelCase/ControlOR95%CI(*P*-value)*I2* (%)PZPTP**MMP9Overall**Dominant1754 / 1702**1.621.03-- 2.53 (0.03)**85.5≤0.0010.800.421.270.24Recessive1754 / 1702**2.691.68 -- 4.29 (≤0.001)**270.20-1.460.14-2.170.06Allelic1754 / 1702**1.511- 2.28 (0.04)**87.8≤0.0010.270.780.340.74TT vs. CC1754 / 1702**3.201.87 -- 5.46 (≤0.001)**500.04-1.040.29-1.900.9CT vs.CC1754 / 1702**1.531.02 -- 2.28 (0.04)**80.8≤0.0010.980.3210.34**MMP3**Dominant305/3421.180.66-2.13 (0.57)00.57-10.31\*\*Recessive305/3420.570.18-1.79 (0.33)88.5≤0.00110.31\*\*Allelic305/3421.110.88-1.41 (0.39)00.9110.31\*\*6A6A vs. 5A5A305/3421.150.62- 2.11 (0.43)00.48-10.31\*\*5A6A vs.5A5A305/3421.240.64 -- 2.39 (0.52)00.5410.31\*\***MMP2Overall**Dominant368 /5521.360.39 -- 4.78 (0.07)90.4≤0.0010.520.600.040.97Allelic368 /5521.150.36 -- 3.61 (0.81)91.9≤0.0010.520.600.140.91CT vs.CC368 /5521.500.52 -- 4.35 (0.45)85.9≤0.0010.520.60-0.100.93\* Egger's test was not calculable

Meta-analysis of MMP-3 (− 1612 5A/6A) and risk of MS {#Sec10}
----------------------------------------------------

Two studies with 305 cases and 342 controls were included. One study was conducted in Serbia \[[@CR45]\] and the other in Iran \[[@CR46]\]. The results of overall population reject any association between *MMP-3* gene *− 1612 5A/6A* SNP and risk of MS across all genotype models including; dominant model (OR = 1.18, 95% CI = 0.66--2.13, *P* = 0.57), recessive model (OR = 0.57, 95% CI = 0.18--1.79, *P* = 0.33), allelic model (OR = 1.11, 95% CI = 0.88--1.41, *P* = 0.39), 6A6A vs. 5A5A model (OR = 1.15, 95% CI = 0.62--2.11, *P* = 0.66), and 5A6A vs. 5A5A model (OR = 1.24, 95% CI = 0.64--2.39, *P* = 0.52). The results of pooled ORs, heterogeneity tests and publication bias tests in different analysis models are shown in Table [3](#Tab3){ref-type="table"}.

*Meta-analysis of MMP-2 (*− 1306 C/T) *and risk of MS* {#Sec11}
------------------------------------------------------

Overall, three studies with 368 cases and 552 controls were eligible for the association between *MMP-2* gene rs243865 SNP and susceptibility to MS. All three studies were conducted in Europe \[[@CR38], [@CR47], [@CR48]\]. Because of TT genotype frequency of zero in both cases and controls, the recessive model and TT vs. CC model were not applicable to calculate. The results of other three models also reject association between *MMP-2* gene rs243865 SNP and MS risk. The results were; dominant model (OR = 1.36, 95% CI = 0.39--4.78, *P* = 0.07), allelic model (OR = 1.15, 95% CI = 0.36--3.61, *P* = 0.81), and CT vs. CC model (OR = 1.50, 95% CI = 0.52--4.35, *P* = 0.45). The results of pooled ORs, heterogeneity tests and publication bias tests in different analysis models are shown in Table [3](#Tab3){ref-type="table"}.

Publication bias and heterogeneity {#Sec12}
----------------------------------

In this study, we used Egger's regression test, Begg's adjusted rank correlation test and visual examination of the funnel plot to measure publication bias. The results of Begg's and Egger's tests for *MMP-9*1562 C/T (rs3918242), *MMP-3* (− 1612 5A/6A), and *MMP-2* (− 1306 C/T) gene polymorphisms showed no evidence of publication bias (Fig. [3](#Fig3){ref-type="fig"}). During our analysis, we have detected some degree of heterogeneity for three SNPs (Table [3](#Tab3){ref-type="table"}). Fig. 3Begg's funnel plot for publication bias test. Each point represents a separate study for the indicated association

Sensitivity analysis {#Sec13}
--------------------

Here, we performed sensitivity analysis only for *MMP-9* gene rs3918242 SNP in order to determine whether sequential omission of the eligible studies affect the final pooled OR. As shown in (Fig. [4](#Fig4){ref-type="fig"}), the result was not changed, confirming the stability of our meta-analytical result. Fig. 4Sensitivity analysis in present meta-analysis investigates the individual influence of studies on pooled results

Discussion {#Sec14}
==========

To date, several surveys have been conducted addressing the possible association between polymorphisms of the MMP gene family, including *MMP-9*1562 C/T (rs3918242), *MMP-3* (− 1612 5A/6A), and *MMP-2* (− 1306 C/T) and risk of MS, resulting in inconsistent and inconclusive results. Through resolving the limitation of insufficient statistical power and small sample size in individual studies, meta-analysis studies confer a beneficial approach to settle the problem of conflict. In order to meet this need, here in this meta-analysis we included the most comprehensive and up-to-date original works to obtain exact approximation with respect to association between MMP gene polymorphisms and MS risk.

Previously, large genome-wide association study (GWAS) did not reveal that MMP9 polymorphisms to be significantly associated with the risk for MS \[[@CR49]\]. Additionally, a meta-analysis performed on the case-control studies from Europe and one Brazilian study and did not indicate a significant association of MMP9 (− 1562 C/T) SNP with and MS susceptibility \[[@CR50]\]. The number of included studies in the meta-analysis was limited and inclusion of further recent studies in Asian populations, like Iran and Egypt, led to significant association of MPP9 polymorphism with MS susceptibility. On the other hand, the role of variations in the MMP9 gene may differ in various populations. Reports have indicated that the T allele was underrepresented only in female MS patients \[[@CR37], [@CR38]\]. It seems that differences in the genetic originality of subjects in different populations as well as the gender of the MS patients are involved in determining the function of MMP gene variations in the etiopathogenesis of MS.

MMPs are enzymes that have proteolytic function and have been attributed with numerous implications in tissue remodeling and development. MMPs, especially MMP-9 (also known as gelatinase B), have been observed to be the primary enzymes involved in the degradation of the BBB in MS setting \[[@CR23], [@CR51]\]. The major function of MMP-9 is to degrade extracellular matrix (ECM) and myelin basic protein (MBP), hence mediating the recruitment of the inflammatory cells into the involved CNS in MS disease \[[@CR52]--[@CR55]\]. MS patients have shown increased cerebrospinal fluid (CSF) and serum levels of MMP-9 \[[@CR56], [@CR57]\]. MMP-9 level has been implied to be a proper marker for the evaluation of clinical type and severity of the disability in MS patients \[[@CR58]\].

Studies have established that two functional SNPs in the promoter region MMP-9 gene, namely rs3918242 and rs3222264, impress the expression of this gene \[[@CR39], [@CR44], [@CR59], [@CR60]\]. In rs3222264 SNP, the − 90 position is involved in double strand DNA opening and exerted by transcription factors and DNA regulatory proteins. In vitro experiments indicated that the C--1562 T SNP play a role in blocking the nuclear repressor protein binding to the promoter region in which this SNP is located, leading to upregulation of MMP-9 expression \[[@CR61]\].

Our meta-analysis indicated significant association of MMP-9 (− 1562 C/T) SNP and risk of MS. Interestingly, all genetic model comparisons, including dominant model (OR = 1.62), recessive model (OR = 2.69), allelic model (OR = 1.51), TT vs. CC model (OR = 3.20), and CT vs. CC model (OR = 1.53), increased the risk of MS susceptibility. The previous meta-analysis by Li et al. in 2017 included 6 studies comprising 1265 MS patients and 1104 controls. The meta-analysis did not show any association of MMP-9 (− 1562 C/T) SNP with MS risk \[[@CR50]\]. However, our meta-analysis, by including 10 studies for MMP-9 (− 1562 C/T) SNP containing 1757 MS subjects and 1702 controls, indicated an increased risk of MS by all genetic models of this polymorphism. Furthermore, we evaluated the possible association of *MMP-3* (− 1612 5A/6A) and *MMP-2* (− 1306 C/T) SNPs and risk of MS to attain more comprehensive conclusion of MMP gene polymorphisms and MS risk. However, we did not find association of these SNPs with MS risk, possibly due to small sample size and little number of studies, which need further evaluations in the future.

Although *MMP-3* (− 1612 5A/6A) and *MMP-2* (− 1306 C/T) SNPs were not associated with MS risk according to our meta-analysis, the role of genetic interactions and haplotypes should not be neglected. In a study, the MMP-9 T allele was not associate with MS risk, however, a synergism was identified between MMP-9 C and MMP-7 G alleles in increasing MS risk by 1.5 times. Furthermore, there was 3.13 times increased MS risk in association with the haplotype MMP-9 T, MMP-7 G, and MMP-2 C (TGC) in comparison to the CAG haplotype \[[@CR28]\]. Therefore, further studies may disclose the association on *MMP-3* (− 1612 5A/6A) and *MMP-2* (− 1306 C/T) SNPs with MS risk in the haplotype analysis.

Although we tried to carry out the most comprehensive meta-analysis of the MMP gene SNPs and the risk of MS, a number of limitations of this meta-analysis study should be remarked. First, the number of studies and sample size for *MMP-3* (− 1612 5A/6A) and *MMP-2* (− 1306 C/T) SNPs in this meta-analysis was relatively small to conclude the role of these SNPs and MS risk. Second, we only searched for articles published in the English language and a number of potential data might be neglected. Third, the current meta-analysis was according to crude analysis of the genetic polymorphisms, and the adjusting the analysis by gender, age, and other environmental factors were not taken into consideration. Fourth, we detected some degrees of heterogeneity for the analyzed SNPs, that might stem from difference in genetic stratification and ethnicity, variety in the environmental factors in different populations, and the detection methods.

Conclusion {#Sec15}
==========

Taken all the evidence into conclusion, this was the first and most comprehensive evaluation of the MMP gene family SNPs in association with MS. Unlike previous meta-analysis, our study detected significant association of MMP-9 (− 1562 C/T) SNP with increased risk of MS. Nonetheless, other polymorphisms were not associated, perhaps due to little sample size. Hence, we acknowledge the further studies with respect to evaluation of other MMP gene SNPs in association with MS, particularly in a haplotype analysis. Furthermore, the role of other factors, like age, gender, and environmental factors in the analysis ahead will hopefully shed further light on the bona fide implication of MMP gene polymorphisms and susceptibility to MS.
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